0001104659-22-085635.txt : 20220803
0001104659-22-085635.hdr.sgml : 20220803
20220803161600
ACCESSION NUMBER: 0001104659-22-085635
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220802
FILED AS OF DATE: 20220803
DATE AS OF CHANGE: 20220803
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nielsen Jack
CENTRAL INDEX KEY: 0001602402
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39450
FILM NUMBER: 221132793
MAIL ADDRESS:
STREET 1: C/O AKEBIA THERAPEUTICS, INC.
STREET 2: 245 FIRST STREET, SUITE 1100
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc.
CENTRAL INDEX KEY: 0001802665
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 822279923
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 630 W GERMANTOWN PIKE
STREET 2: SUITE 215
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
BUSINESS PHONE: (484) 539-9800
MAIL ADDRESS:
STREET 1: 630 W GERMANTOWN PIKE
STREET 2: SUITE 215
CITY: PLYMOUTH MEETING
STATE: PA
ZIP: 19462
4
1
tm2222520-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-08-02
0
0001802665
Harmony Biosciences Holdings, Inc.
HRMY
0001602402
Nielsen Jack
C/O HARMONY BIOSCIENCES HOLDINGS, INC.
630 W. GERMANTOWN PIKE, SUITE 215
PLYMOUTH MEETING
PA
19462
1
0
0
0
Common Stock
2022-08-02
4
S
0
75117
55.22
D
3300261
I
See Footnote
The shares are held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the General Partner of Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. As a managing member of Vivo Capital VIII, LLC, Jack Nielsen shares voting and dispositive power with respect to the shares held of record by Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P. with other managing members, but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein.
The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2021.
The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $55.00 to $55.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnote (3) to this Form 4.
/s/ Christian Ulrich, Attorney-in-fact for Jack Bech Nielsen
2022-08-03